Avatrombopag in patients with early versus chronic immune thrombocytopenia

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses a study of avatrombopag in patients with early versus chronic immune thrombocytopenia (ITP). At present, this drug, which is considered to be more convenient than eltrombopag due to its lower rate of side effects, is only approved in the chronic form of ITP. However, this study showed its comparable efficacy and safety in those patients with early ITP. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

• #education
• #speaker_hanny_al_samkari
• #institution_massachusetts_general_hospital
• #event_ash_2023
• #format_interview
• #subject_immune_thrombocytopenia
• #subject_non_malignant
• #field_treatment
• #medicines_eltrombopag
• #medicines_avatrombopag
• #early_itp
• #chronic_itp
• #side_effects
• #dietary_restriction
• #efficacy
• #safety